La chaîne d'options affiche les données clés des options sur actions de Immunic à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Immunic..

Immunic (NASDAQ:IMUX) Stock, Chaîne d'Options

IMMUNIC INC

Immunic

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Immunic Inc

Offerings

Press Releases

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

Immunic to Participate in Investor, Scientific and Industry Conferences in June

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Earnings

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Immunic to Participate in Investor and Scientific Conferences in September

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis

Penny Stocks

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

Immunic to Participate in Scientific and Investor Conferences in October

IMUX

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

Atara Biotherapeutics, Inc. - Common Stock

Atara Biotherapeutics

aTyr Pharma

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

Clene

Connect Biopharma Holdings Limited - Ordinary Shares

Connect Biopharma Hldgs

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Coya Therapeutics

Fortress Biotech

InflaRx

Immix Biopharma

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

Lite Strategy

Macrogenics

Metagenomi

Quince Therapeutics

Repare Therapeutics

Spruce Biosciences

Shattuck Labs

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

Whitehawk Therapeutics, Inc. - Common Stock

Comments

Immunic

Immunic (IMUX) Options

Immunic (NASDAQ:IMUX) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL